The use of sustained FSH (corifollitropin alfa) for ovarian stimulation in in-vitro fertilization

Abstract

Introduction: Ovarian stimulation regimes have been modified to a shorter duration of stimulation, fewer injections and reduced ovarian hyperstimulation rate. Corifollitropin alfa has sustained FSH activity and is able to replace a week of daily injections with an one time injection, reducing physical stress for IVF patients. Objective: Investigate the efficacy and safety of corifollitropin alfa for ovarian stimulation in IVF. Methods: Ovarian stimulation was performed using GnRH antagonist protocol. Corifollitropin alfa was injected on day 2 of the cycle. GnRH antagonist 0,25mg was started from day 5 after the corifollitropin alfa injection. When there were at least 2 follicles ≥ 17mm, hCG was administered. If patients had more than 20 developing follicles, hCG was replaced by GnRH agonist. Oocyte pick-up was done 36 hours after hCG injection. Embryo transfer was on day 2. Results: There were 57 oocyte donors and 26 IVF patients who had corifollitropin alfa used for ovarian stimulation.The mean number of oocytes retrieved was 14-16 and the mean number of embryos was 9. All cycles had extra embryos suitable for freezing. The pregnancy rate was 37.5% and implantation rate was 18-23%. There was one case of mild ovarian hyperstimulation. Conclusion: Corifollitropin alfa is effective, safe and convenient for patients undergoing ovarian stimulation for IVF.